Recruiting Head and Neck Cancer Studies in Palo Alto
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incur...
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head an...
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unres...
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back afte...
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurre...
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of impro...
About Head and Neck Cancer Clinical Trials in Palo Alto
Head and neck cancers develop in the mouth, throat, larynx, sinuses, or salivary glands. HPV-related oropharyngeal cancers have been increasing in prevalence. Treatment includes surgery, radiation, chemotherapy, and immunotherapy.
There are currently 6 head and neck cancer clinical trials recruiting participants in Palo Alto, CALIFORNIA. These studies are seeking a combined 1,714 participants. Research is being sponsored by Merus N.V., BioNTech SE, National Cancer Institute (NCI). Clinical trial participation is free and participants receive study-related medical care at no cost.
Head and Neck Cancer Clinical Trials in Palo Alto — FAQ
Are there head and neck cancer clinical trials in Palo Alto?
Yes, there are 6 head and neck cancer clinical trials currently recruiting in Palo Alto, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Palo Alto?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you about next steps.
Are clinical trials in Palo Alto free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Palo Alto studies also compensate for your time and travel.
What head and neck cancer treatments are being tested?
The 6 active trials in Palo Alto are testing new therapies including novel drugs, biologics, and treatment approaches for head and neck cancer.
Data updated March 2, 2026 from ClinicalTrials.gov